Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult Participants

作者：Amparo L. Figueroa, Bethany Girard, Darin K. Edwards, Arshan Nasir, Kimball Johnson, Steven Hack, Xin Cao, Elizabeth de Windt, Verónica Urdaneta, Frances Priddy, Rituparna Das, David C. Montefiori, Spyros Chalkias · 发表于：Open Forum Infectious Diseases · 年份：2025 · DOI：10.1093/ofid/ofaf705 · 被引用次数：4 · 研究领域：SARS-CoV-2 and COVID-19 Research、Peripheral Neuropathies and Disorders、Animal Virus Infections Studies

In this ongoing, open-label, phase 3b/4 study, JN.1- and KP.2-encoding monovalent mRNA-1273 vaccines elicited robust neutralization of vaccine-matched variants (JN.1, KP.2) and cross-neutralized JN.1 subvariants circulating during the study (September 2024-November 2024; KP.3.1.1, XEC, LP.8.1) in vaccinated adults, showing reduced cross-neutralization against all subvariants tested. No safety concerns were identified.